Immunotherapy startups look to engineer macrophages to fight solid tumors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International Open Access 24 November 2023
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Molecular Cancer Open Access 30 January 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Cancer-eating immune cells kitted out with CARs. Nat Biotechnol 38, 509–511 (2020). https://doi.org/10.1038/s41587-020-0520-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0520-5
This article is cited by
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Molecular Cancer (2023)
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International (2023)
-
AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells
Nature Biomedical Engineering (2023)
-
Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo
Nature Immunology (2022)